Clinical Trials Logo

Facies clinical trials

View clinical trials related to Facies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06465641 Not yet recruiting - Clinical trials for ADHD - Combined Type

Methylphenidate in KBG Syndrome: N-of-1 Series

KBGS_N_of_1
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial] is to learn about the effect of methylphenidate in children and adolescents with KBG syndrome. The main question it aims to answer is: • What is the effectiveness of methylphenidate on attention deficit and ADHD-related symptoms in children and adolescents with KBG syndrome? Participants will receive multiple blocks of treatment with methylphenidate and placebo and fill out various questionnaires.

NCT ID: NCT06349096 Not yet recruiting - Clinical trials for Facial Skin Wrinkles

Safety And Efficacy Investigation Of The Effects Of ClearLift Q-Switched Nd:Yag 1064nm Laser Module In The Treatment Of Facial Skin Wrinkles

Start date: March 26, 2024
Phase: N/A
Study type: Interventional

Alma Lasers ClearLift is a fractional non-ablative Q-Switched laser, allowing practitioners to use the benefits of a high intensity QS laser for the treatment of aged skin. Alma Harmony ClearLift uses a fractional QS laser to achieve a deep mechanical effect beneath the epidermis via a photoacustic effect. This creates a controlled dermal wound while leaving the epidermis intact. The wound healing process stimulates growth of new collagen, skin contracture and tightening. This procedure is virtually painless with no downtime and is safe for all skin types. Based on this background, we have considered an interest to design a study aimed at assessing the efficacy and safety of a treatment course with ClearLift Module in patients with facial skin wrinkles

NCT ID: NCT05699187 Not yet recruiting - Facial Injuries Clinical Trials

Face Transplantation

Start date: March 2023
Phase: N/A
Study type: Interventional

Face allotransplantation will be performed in facial trauma patients. Immune suppression will primarily be provided according to standard three-drug regimen. The primary outcome to be evaluated in the proposed trial is face allograft acceptance.

NCT ID: NCT05222698 Not yet recruiting - Facial Paralysis Clinical Trials

Free Neurovascularized Muscle Transfer in Facial Reanimation of Long-standing Facial Palsy Patients

Start date: April 2022
Phase: N/A
Study type: Interventional

The use of free Neurovascularized muscles like free latissimus and gracillis muscles for reanimation of long-standing facial palsy patients using the hypoglossal nerve for innervating these muscles

NCT ID: NCT05177380 Not yet recruiting - Rehabilitation Clinical Trials

Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis

PREVISS
Start date: September 2022
Phase: N/A
Study type: Interventional

Systemic sclerosis is a rare autoimmune disorder characterized by microangiopathy, activation of the immune system, and sclerosis of tissues including the skin. Facial involvement is frequent and disabling. It causes significant functional and aesthetic discomfort, and a major deterioration in quality of life. It results in a loss of suppleness of the skin and subcutaneous tissues, dysfunction of the temporomandibular joint, peribuccal rhagades, microstomia, and dry mouth causing difficulties in mouth opening, feeding, dental care, and weight loss. Facial involvement in systemic sclerosis can be assessed using the Mouth Handicap in Systemic Sclerosis (MHISS) score, a validated patient questionnaire assessing the functional and aesthetic consequences of systemic sclerosis on the face. Although common and disabling, facial involvement is underestimated and poorly managed. Immunosuppressive and/or anti-fibrosis drugs are not very effective. Facial rehabilitation could significantly improve the mouth handicap but facial rehabilitation is not currently performed in standard care in systemic sclerosis patients. The aim of the study is to evaluate the efficacy of a personalized rehabilitation program vs standard care in facial involvement of systemic sclerosis patients.

NCT ID: NCT04745260 Not yet recruiting - Anxiety Clinical Trials

Intranasal Fentanyl in Combination With Midazolam Versus Midazolam Alone for Pediatric Facial Laceration Repair

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the effectiveness of a combination of intranasal fentanyl and intranasal midazolam to intranasal midazolam alone for analgesia and anxiolysis in patients presenting for facial laceration repair in the pediatric emergency department.

NCT ID: NCT04499040 Not yet recruiting - Clinical trials for Tricho Hepato Enteric Syndrome

Clinical and Biological Characterization of Patients and Collection of Samples

THE-RNA
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Objectives: Collect clinical and biological data about patients with SD/THE, collect samples of patients; create a secure on line database to collect worldwide data about SD/THE Partners : APHM, HCL, APHP Currently10 patients (8 with TTC37 mutations and 2 with SKIV2l mutations) present a SD/THE and are managed in France in 5 different centers (Marseille, Paris Trousseau, Paris Necker, Paris Robert Debrés, and Lyon). Most of them are followed in hepato-gastro-enterology units for their intractable diarrhea. Three aspects of the disease: intractable diarrhea, immune defect and liver disease are responsible for the main part of the burden of the disease .For each aspect, the investigators will propose a close follow-up with collection of clinical, biochemical, functional and microbial data. Collect of clinical date: during a programmed consultation clinical data about symptom will be collected twice a year. A detailed form will be used for better delineation of the symptoms. These data included growth, symptom (diarrhea, pain …), and clinical signs. Most of these children have recurrent sample for follow up. During them some blood will be take for study the immune side but also the platelet function.

NCT ID: NCT03836638 Not yet recruiting - Aging Clinical Trials

The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Botulinum toxin is approved by the FDA for the treatment of facial wrinkles. Patients are usually older than 45 years and their main demand is to treat pre-existing facial wrinkles. However with the increasing popularity of this technique, younger patients, aged 25 to 35 years, are now seeking botulinum toxin injection as a preventive measure for rhytides. The usual dose used for the treatment of facial rhytides in a female patient older than 45 years is 50 units. No consensus exists concerning the dose of botulinum toxin that should be used in younger patients. Hypothesis: lower dose of botulinum toxin is sufficient to give good and long lasting results in young patients. The objective of this randomized open-label study is to evaluate the effect of lower doses of Botulinum toxin on the facial rythides in young patients.

NCT ID: NCT02923219 Not yet recruiting - Facies Clinical Trials

The Clinical Application of Adipose-Derived Stem Cells on Facial Rejuvenation

ADSCs
Start date: January 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the adipose-derived stem cells therapy is effective in the treatment of facial rejuvenation.